AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12799312
Drug: Intravenous C-peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous C-peptide during NOS blockade
Trial: 11060747
Drug: Insulin sensitiser
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin sensitiser drugs
Trial: 8328549
Drug: Tetracycline hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline hydrochloride 1 g/day
Trial: 29880175
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg drospirenone/30 μg ethinyl estradiol (OC)
Trial: 29880175
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of OC and 1700 mg metformin
Trial: 26950683
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g transdermal T gel (TT)
Trial: 26950683
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral aromatase inhibitor (AI)
Trial: 24874317
Drug: Tenoxicam (texamen)
DrugBank: Tenoxicam (DB00469)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (texamen) 20 mg daily for 7 days with therapeutic exercises
Trial: 22220822
Drug: Amoxicillin-metronidazole combination
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-metronidazole combination (500 mg of each, three times a day for 7 days) and One-Stage-Full-Mouth-Disinfection (OSFMD)
Trial: 10500075
Drug: UDCA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA plus budesonide (3 mg three times daily)
Trial: 8934801
Drug: Astemizole 10
RxNorm normalized name: astemizole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole 10 mg/day
Trial: 1898300
Drug: Aspartame (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (50 mg/kg body weight)
Trial: 7129725
Drug: Heating treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heating treatment at 45 degrees C
Trial: 27858987
Drug: Ruxolitinib 10
RxNorm normalized name: ruxolitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 10 mg BID (n=54)
Trial: 19281327
Drug: Empirical antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antifungal treatment (amphotericin B deoxycholate 1 mg/kg/day or liposomal amphotericin 3 mg/kg/day)
Trial: 19281327
Drug: Preemptive antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive antifungal treatment (amphotericin B deoxycholate 1 mg/kg/day or liposomal amphotericin 3 mg/kg/day)
Trial: 19281327
Drug: Preemptive antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive antifungal treatment
Trial: 17290726
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (nicotine inhaler and bupropion)
Trial: 15318311
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with suspected acute rejection (Group G)
Trial: 11771440
Drug: Adjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoradiation therapy following complete resection of gastric cancer
Trial: 11771440
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy following resection of stage III colon cancer
Trial: 11771440
Drug: Adjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoradiation therapy for stages II and III rectal cancer
Trial: 11771440
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation therapy for esophageal cancer
Trial: 9158353
Drug: Meperidine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (0.6 microgram/ml, 40 mg/h)
Trial: 9158353
Drug: Meperidine (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (1.8 micrograms/ml, 120 mg/h)
Trial: 3318475
Drug: timolol 0.5%-pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol 0.5%-pilocarpine 2% twice a day
Trial: 3318475
Drug: timolol 0.5%-pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol 0.5%-pilocarpine 4% twice a day
Trial: 23098680
Drug: Melatonin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (0.5 mg, 2 mg, 6 mg, 12 mg)
Trial: 20647477
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) injection with 2,000 microg mouse gp100 DNA
Trial: 18704636
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m² on days 1, 8, and 15 of a 28-day cycle
Trial: 18704636
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m² (with dose reduction to 800 mg/m² in 5 patients due to toxicity)
Trial: 18704636
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m²
Trial: 15965168
Drug: Classic laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classic laser treatment
Trial: 15965168
Drug: Light laser
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light laser treatment
Trial: 8916634
Drug: Relapse prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse prevention therapy
Trial: 1679254
Drug: Continuous low
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low dose antipsychotic medication
Trial: 1679254
Drug: Intermittent or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent or targeted medication
Trial: 1679254
Drug: Established moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established moderate dose antipsychotic medication
Trial: 6341252
Drug: Cefroxadine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefroxadine (1 g t.i.d. for five days)
Trial: 6341252
Drug: Cephalexin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (1 g t.i.d. for five days)
Trial: 31113752
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 250 mg twice daily for 6 months
Trial: 24259653
Drug: Doripenem 500
RxNorm normalized name: doripenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doripenem 500 mg (1-hour infusion) every 8 hours
Trial: 24259653
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g (0.5-hour infusion) every 8 hours
Trial: 17986324
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of 20 ml Carbostesin 0.25% at the end of the operation
Trial: 17986324
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml placebo (0.9% Saline) injection
Trial: 12668574
Drug: Indinavir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 800 mg every 8 h
Trial: 12668574
Drug: Indinavir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 800 mg + ritonavir 100 mg every 12 h
Trial: 1866408
Drug: nCPAP-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP-therapy
Trial: 1866408
Drug: Theophylline 375-400
RxNorm normalized name: theophylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 375-400 mg in the evening
Trial: 1866408
Drug: O2-therapy by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O2-therapy by 21/min, by nasal prongs
Trial: 6406165
Drug: High-calorie and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calorie and protein supplement
Trial: 27657476
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose diuretics (HD)
Trial: 27657476
Drug: Low diuretic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low diuretic efficiency (DE)
Trial: 27657476
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration
Trial: 24312305
Drug: High-exposure group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-exposure group (antimicrobial treatment with piperacillin/tazobactam, meropenem, ciprofloxacin)
Trial: 24312305
Drug: Standard-of-care (SOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC group, antimicrobial treatment with cefuroxime)
Trial: 20374604
Drug: Cosmetic regimen
RxNorm normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosmetic regimen (n = 99): SPF 30 moisturizing lotion with 5% niacinamide, peptides, antioxidants; moisturizing cream with niacinamide and peptides; targeted wrinkle product with niacinamide, peptides, and 0.3% retinyl propionate
Trial: 20374604
Drug: Prescription regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription regimen (n = 97): 0.02% tretinoin plus moisturizing SPF 30 sunscreen
Trial: 17712656
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 1000 mg, twice daily
Trial: 17712656
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 500 mg, twice daily
Trial: 10759664
Drug: Terazosin (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (1-2 mg daily, 0.5 mg twice daily for 2 weeks, then 1 mg twice daily for 2 weeks)
Trial: 10759664
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg daily for 4 weeks)
Trial: 8997678
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg 1 hour presurgery and 400 mg postsurgery)
Trial: 6403962
Drug: Pentobarbital 200
RxNorm normalized name: PENTobarbital 200 mg rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital 200 mg
Trial: 6403962
Drug: Pentobarbital 400
RxNorm normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentobarbital 400 mg
Trial: 6403962
Drug: Pentobarbital 600
RxNorm normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentobarbital 600 mg
Trial: 30264977
Drug: DHEA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (100 mg/day for 4 weeks)
Trial: 24621109
Drug: BDP/FF 200/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF 200/12 μg twice daily
Trial: 24621109
Drug: FP/S 500/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/S 500/50 μg twice daily
Trial: 21933347
Drug: Bayesian approach
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayesian approach for lithium drug monitoring
Trial: 15191772
Drug: Haemoglobin sub-divided
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin sub-divided by 1.0 g/dL increments
Trial: 11589263
Drug: Ketoprofen lysine
RxNorm normalized name: ketoprofen lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen lysine salt (KLS) mouthwash (10 mL diluted in 100 mL of water, gargled twice daily for up to 7 days)
Trial: 11589263
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride (BH) mouthwash (15 mL, 22.5 mg, gargled twice daily for up to 7 days)
Trial: 2686744
Drug: Cefixime 100
RxNorm normalized name: cefixime 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 100 mg once daily (6 months to 5 years), 200 mg once daily (5 to 10 years), 300 mg once daily (10 to 16 years)
Trial: 2686744
Drug: Amoxycillin 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin 62.5 mg tds (6 months to 1 year), 125 mg tds (1 to 7 years), 250 mg tds (7 to 16 years)
Trial: 30572072
Drug: Exception from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exception from informed consent (EFIC) implementation strategies including community consultation (CC) and public disclosure (PD) methods.
Trial: 30572072
Drug: Community consultation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community consultation (CC) methods such as social media advertising, random digit dialing surveys, working with city officials, and websites with embedded surveys.
Trial: 30572072
Drug: Time from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time from community consultation (CC) to study approval.
Trial: 24341820
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) guided antibiotic therapy
Trial: 24341820
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with antibiotics at physician's discretion (Control)
Trial: 21488594
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with fluorouracil and folinic acid (de Gramont protocol)
Trial: 21488594
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for stage II disease
Trial: 15156311
Drug: Acemetacin (ACE)
RxNorm normalized name: acemetacin
DrugBank: Acemetacin (DB13783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemetacin (ACE) 90 mg bid for 6 weeks
Trial: 15156311
Drug: Celecoxib (CEL)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib (CEL) 200 mg bid for 6 weeks
Trial: 11410698
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation (ES) over the abdomen and posterior back muscles in addition to physical therapy for 6 weeks
Trial: 11410698
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving only physical therapy for 6 weeks
Trial: 9579280
Drug: Oral tacrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tacrine treatment
Trial: 2789364
Drug: Ponsinomycin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponsinomycin 800 mg syrup administered during a standard meal
Trial: 2789364
Drug: Ponsinomycin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponsinomycin 800 mg syrup administered 2 hours before a standard meal
Trial: 21814211
Drug: Imidapril 10
RxNorm normalized name: imidapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril 10 mg (titrated to 20 mg for nonresponders)
Trial: 21814211
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg (titrated to 32 mg for nonresponders)
Trial: 16488084
Drug: Olanzapine, 5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine, 5-20 mg/day
Trial: 16488084
Drug: Current therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current therapy (pre-study antipsychotic medication)
Trial: 324835
Drug: Chlorpropamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpropamide (100 mg. O.D.)
Trial: 324835
Drug: Tolbutamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide (500 mg. b.i.d.)
Trial: 324835
Drug: Phenformin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenformin (50 mg. O.D.)
Trial: 324835
Drug: Acetohexamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetohexamide (250 mg. O.D.)
Trial: 23530305
Drug: Living Well
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living Well By Faith intervention (8-week program, classes held twice a week including educational workshops and exercise sessions)
Trial: 19211452
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 to 325 mg/d)
Trial: 19211452
Drug: Aspirin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (any dose)
Trial: 16492440
Drug: Fortified maternal
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fortified maternal milk thickened by 1.5 g of precooked starch per 100 mL of milk (milk B)
Trial: 14687309
Drug: CVT‐E002 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVT‐E002 (200 mg, oral, twice daily)
Trial: 10930901
Drug: OMC 4
RxNorm normalized name: Oxymorphone Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC 4 (4 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin followed by 6 days b.d. 20 mg omeprazole and placebo antibiotics)
Trial: 10930901
Drug: OMC 7
RxNorm normalized name: iron bg/vit C/vit B12/stomc 70 mg-150 mg-10 mcg-100 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC 7 (7 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin followed by 3 days b.d. 20 mg omeprazole and placebo antibiotics)
Trial: 10930901
Drug: OMC 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC 10 (10 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin)
Trial: 10930901
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatments (OMC 4, OMC 7, OMC 10)
Trial: 30715261
Drug: (Peg)IFN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Peg)IFN therapy
Trial: 30715261
Drug: G3BP2 G-allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G3BP2 G-allele
Trial: 27188919
Drug: Liquid contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid contrast agent
Trial: 27188919
Drug: Semisolid contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semisolid contrast agent
Trial: 27188919
Drug: Liquid contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid contrast agent in patients with severe hiatal hernia
Trial: 27188919
Drug: Liquid contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid contrast agent in patients with mild hiatal hernia
Trial: 27188919
Drug: Liquid contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid contrast agent in patients with no hiatal hernia
Trial: 20307215
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) - 1-3 injections of 1.25 mg
Trial: 20307215
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (IVT) - 1-3 injections of 2 mg
Trial: 18562489
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy administered subcutaneously at 0.05 mg/kg per day until growth velocity was 1 cm/6 months
Trial: 18562489
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy in children with a mutation in PTPN11
Trial: 8738857
Drug: Cholestyramine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (4 g twice daily) concurrent with valproic acid (250 mg)
Trial: 8738857
Drug: Cholestyramine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (4 g twice daily) staggered with valproic acid (250 mg, 3 hours apart)
Trial: 8738857
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid alone (250 mg)
Trial: 1860196
Drug: streptokinase plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: streptokinase plus heparin
Trial: 1860196
Drug: heparin (when
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin (when begun 12 hours after intravenous thrombolysis)
Trial: 10227333
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate nasal spray
Trial: 28431551
Drug: Guided Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-based cognitive behavioural therapy (iCBT) intervention
Trial: 22111350
Drug: Pentazocine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 0.3 mg x kg(‐1)
Trial: 22111350
Drug: Pentazocine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 0.6 mg x kg(‐1)
Trial: 8311488
Drug: KW-2307 single
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 single administration at 10 mg/m2 escalated to 35 mg/m2
Trial: 8311488
Drug: KW-2307 repeated
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 repeated administration at 30 mg/m2 for 4 weeks
Trial: 8311488
Drug: KW-2307 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 (both administration types)